Jazz Pharmaceuticals (JAZZ) announced the completion of patient enrollment in two phase III studies evaluating the safety and efficacy of its lead pipeline candidate JZP-110.
Biotech major, Amgen, Inc. (AMGN), announced that its multiple myeloma drug Kyprolis did not meet the primary endpoint in a phase III head-to-head CLARION study with Velcade.
- Zacks•2 days ago
Amgen Inc. (AMGN), along with its partner UCB S.A. (UCBJF), a global biopharmaceutical company, announced that the FDA has accepted their Biologics License Application (BLA) for romosozumab for the treatment of osteoporosis.
Anika Therapeutics Inc. (ANIK)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||46.70 x 1600|
|Ask||46.80 x 100|
|Day's Range||46.48 - 46.85|
|52wk Range||30.94 - 54.96|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||20.36|
|Avg Vol (3m)||121,329|
|Dividend & Yield||N/A (N/A)|